文献速递乳腺MR

基于治疗前DCE-MRI的列线图预测三阴性乳腺癌新辅助化疗后病理缓解

Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
PubMed 文献 · Eur Radiol · 2021-11-12

该研究纳入108例接受新辅助化疗后手术的三阴性乳腺癌女性患者,按4:1随机分为建模组(n=87)和验证组(n=21)。基于治疗前DCE-MRI测量的肿瘤体积、达峰时间(TTP)及雄激素受体(AR)状态构建列线图预测病理完全缓解(pCR),建模组和验证组AUC分别为0.84(95% CI: 0.75-0.93)和0.79(95% CI: 0.59-0.99)。

要点

  • 治疗前DCE-MRI的肿瘤体积和TTP是预测三阴性乳腺癌新辅助化疗后pCR的独立影像因素。
  • 联合影像与AR状态的列线图在建模组AUC为0.84,验证组AUC为0.79,有较好预测效能。
  • 该列线图有助于个体化预测pCR概率并辅助治疗决策。

局限性

  • 验证组样本量仅21例,AUC置信区间宽。
  • 回顾性单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop a nomogram based on pretreatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).

METHODS: A total of 108 female patients with TNBC treated with neoadjuvant chemotherapy followed by surgery between January 2017 and October 2020 were enrolled. The patients were randomly divided into the primary cohort (n = 87) and validation cohort (n = 21) at a ratio of 4:1. The pretreatment DCE-MRI and clinicopathological features were reviewed and recorded. Univariate analysis and multivariate logistic regression analyses were used to determine the independent predictors of pCR in the primary cohort. A nomogram was developed based on the predictors, and the predictive performance of the nomogram was evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). The validation cohort was used to test the predictive model.

RESULTS: Tumor volume measured on DCE-MRI, time to peak (TTP), and androgen receptor (AR) status were identified as independent predictors of pCR. The AUCs of the nomogram were 0.84 (95% CI: 0.75-0.93) and 0.79 (95% CI: 0.59-0.99) in the primary cohort and validation cohort, respectively.

CONCLUSIONS: Pretreatment DCE-MRI could predict pCR after NAC in patients with TNBC. The nomogram can be used to predict the probability of pCR and may help individualize treatment.

KEY POINTS: • Pretreatment DCE-MRI findings can predict pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with triple-negative breast cancer. • A nomogram based on the independent predictors of tumor volume measured on DCE-MRI, time to peak, and androgen receptor status could help personalized cancer treatment in TNBC patients.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li, Chen, Zhao, et al. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer. Eur Radiol. 2021. PMID: 34767068. doi:10.1007/s00330-021-08291-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。